HIV Stocks List

Related ETFs - A few ETFs which own one or more of the above listed HIV stocks.

HIV Stocks Recent News

Date Stock Title
Aug 1 GSK US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Aug 1 GSK GSK wins FDA nod to expand Jemperli label in uterine cancer
Aug 1 GSK Who's to blame as Moderna's stock falls amid slashed guidance?
Jul 31 RENB Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
Jul 31 GSK GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter
Jul 31 GSK GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)
Jul 31 GSK GSK plc (GSK) Q2 2024 Earnings Call Transcript
Jul 31 GSK British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
Jul 31 GOVX Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Jul 31 GOVX GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Jul 31 GSK ViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1
Jul 31 GSK GSK dips as vaccine headwinds overshadow guidance raise
Jul 31 GSK GSK (GSK) Tops Q2 Earnings and Revenue Estimates
Jul 31 GSK GSK reports Q2 results, updates FY guidance
Jul 31 GSK GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales
Jul 31 GSK Drugs firm GSK raises targets after strong cancer and HIV treatment sales
Jul 30 GSK GSK shingles vaccine cuts dementia risk
Jul 30 GSK GSK Q2 2024 Earnings Preview
Jul 30 GOVX GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Jul 30 OSUR OraSure Technologies, Inc. (NASDAQ:OSUR) is a favorite amongst institutional investors who own 81%
HIV

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. In most cases, HIV is a sexually transmitted infection and occurs by contact with or transfer of blood, pre-ejaculate, semen, and vaginal fluids. Non-sexual transmission can occur from an infected mother to her infant during pregnancy, during childbirth by exposure to her blood or vaginal fluid, and through breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
HIV infects vital cells in the human immune system, such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including pyroptosis of abortively infected T cells, apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8+ cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections, leading to the development of AIDS.

Browse All Tags